Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 18/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8655908 | 0.86 | ALDH1A1 (0.41) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL5243918 | 0.81 | TXNRD1 (0.57) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL15822128 | 0.81 | TXNRD1 (0.61) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL14413499 | 0.80 | TXNRD1 (0.56) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL9379235 | 0.80 | ALDH1A1 (0.46) | MAPTRAB9A | |
| SCHEMBL2258349 | 0.79 | PIN1 (0.46) | TXNRD1MAPTMAPK1RAB9A | |
| SCHEMBL621047 | 0.78 | TXNRD1 (0.54) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL16750521 | 0.78 | TXNRD1 (0.51) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL26930935 | 0.78 | TXNRD1 (0.54) | TXNRD1GSRS1PR4MAPTS1PR1 | |
| SCHEMBL8657532 | 0.77 | ALDH1A1 (0.46) | TXNRD1GSRS1PR4MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2021-08-19 | — | — | US | disclosed |
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2019-11-21 | — | — | US | disclosed |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3078374-B1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | UNIV VANDERBILT (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180271835-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2018-09-27 | — | — | US | disclosed |
| US-9895351-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY | 2016-10-20 | — | — | US | disclosed |
| EP-3078374-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9346803-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| US-7235550-B2 | Polycyclic azaindole compounds | LES LABORATOIRES SERVIER (FR) | 2007-06-26 | — | — | US | disclosed |
| US-7202266-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-6667304-B2 | Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide | LES LABORATOIRES SERVIER (FR) | 2003-12-23 | — | — | US | disclosed |
| US-20030134847-A1 | New polycyclic azaindole compounds | GUILLAUMET GERALD (FR) | 2003-07-17 | — | — | US | disclosed |
| US-20030105087-A1 | For therapy of melatoninergic disorders | GUILLAUMET GERALD (FR) | 2003-06-05 | — | — | US | disclosed |
| EP-1092717-B1 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-01-08 | — | — | EP | disclosed |
| US-6495543-B1 | TREATING OR PREVENTING MELATONINERGIC DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-12-17 | — | — | US | disclosed |
| EP-1092717-A2 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | TXNRD1 715/4885GSR 735/4885S1PR4 2862/4885 |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | TXNRD1 715/4885GSR 735/4885S1PR4 2862/4885 |
| US-20180271835-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | TXNRD1 715/4885GSR 735/4885S1PR4 2862/4885 |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | TXNRD1 715/4885GSR 735/4885S1PR4 2862/4885 |
| US-20030134847-A1 | New polycyclic azaindole compounds | AZI2, DRD3, CCNI | TXNRD1 4406/4885GSR 2719/4885S1PR4 2133/4885 |
| US-20030105087-A1 | For therapy of melatoninergic disorders | MTNR1A, MTNR1B, TPH1 | TXNRD1 552/4885GSR 192/4885S1PR4 834/4885 |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | TXNRD1 1185/4885GSR 1547/4885S1PR4 1496/4885 |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | TXNRD1 715/4885GSR 735/4885S1PR4 2862/4885 |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | TXNRD1 715/4885GSR 735/4885S1PR4 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.